			M	,	
		pal Investigator Johnen	Train	nee Investigator (if any)	Q
App	lica	tion No. 824-038P		orting Agency (if Non-ICDDR,B)	
Tit	le o	of Study Industrial the effect		est/status:	
\a	LADAS	I Read -	(1)	· · ·	
र्त	19 DENT	st-feeding -pon severity of	()		•
Hal	hoyu	1- Specific diarrhoes at 10000	2 3	Continuation with change	
				No change (do not fill out re	
Cir	cle :	the appropriate answer to each of a	the fo	llowing (If Not Applicable and	
1.			5/	Will signed consent for by	te <u>NA</u>)
	(a)	Ill subjects $\sqrt{2}$ (Yes) No	7	Will signed consent form be r (a) From subjects	
	(b)	Non-ill subjects \$3 / Yes (No)	-f		Yes (No)
	(c)	Non-ill subjects Yes No Minors or persons	1	1	
		under guardianship 🚉 (Yes) No	, 6.	(if subjects are minors)	Yes (No)
2.	Does	s the study involve:	/ 0.	Will precautions be taken to	1
	(a)	Physical risks to the	7.	anonymity of subjects (Yes No
		subjects Yes No		Check documents being submitted Committee:	ed herewith to
	(b)	Social Risks Yes No			
	(c)	Psychological risks		Umbrella proposal - Init:	ially submit a
		to subjects Yes (No)		overview (all other requi	irements will
	(d)	Discomfort to subjects Yes (No		be submitted with individ	lual studies).
	(e)	Invasion of privacy Yes' (a)		Protocol (Required)	
	(f)	Disclosure of informa-		Abstract Summary (Require	ed)
		tion damaging to sub-		Statement given or read t	o subjects on
		ject or others Yes No	•	nature of study, risks, t	ypes of quest
3.	Does	the study involve:		ions to be asked, and rig	tht to refuse
	(a)	Use of records, (hosp-		to participate or withdra	w (Required)
		ital, med_cal, death,		Informed consent form for	subjects
		birth or other) (es) No		Informed consent form for	parent or
	(b)	Use of fetal tissue or		guardian	
	-	abortus Yes (No		Procedure for maintaining	confidential-
	(c)	Use of organs or body		ity	
		fluids / Yes No		Questionnaire or intervie	w schedule *
	Are :	subjects clearly informed about:		* If the final instrument is n	ot completed
	(a)	Nature and purposes of		prior to review, the following	ng information
		study (Yes) No)		should be included in the ab	Stract summary
	(b)	Procedures to be		1. A description of the are	as to be
	(-)	followed including	a a ~	covered in the questionn	aire or
-		23 + 2	As flow		considered
	(c)	Physical mint	v (either sensitive or which	h would
	(d)	Sensitive questions (Yes) No	Surecila	constitute an invasion of	f privacy.
			fronted	1	specific
	(f)	Right to refuse to	4101-0-	questions to be asked in	the sensitive
		participate or to with-		areas.	•
		draw from the 1		3. An indication as to when	the question-
1	(g)	Confidential handling		naire will be presented t	to the Cttee.
		of data "		for review.	
(Compensation 6/or treat No		•	
`	,	ment where there are risks	١	* Not necessary - Their is a	reposition
		or privacy is involved in) .	M mil missing	` `
			/	strdy	•
-		any particular procedure Yes No/		V c	
e ag	ree	to obtain approval of the Ethical	Revio	w Committee kan	
ivol	ving	the rights and welfare of subject	s befo	ore making such changes	

Office White and welfare of subjects before making such change.

Principal Investigator

Trainee

SECTION I - RESEARCH PROTOCOL (PILOT)

ICDDR,B LIBRA **DHAKA 1212**

Title:

Evaluation of the Effect of Breastfeeding Upon the Severity of Pathogen-Specific Diarrhoea at ICDDR, B.

2. Principal Investigator: John D. Clemens

Co-Investigators:

N. Shahid and B. Stanton

3. Starting Date: September, 1984

4. Completion Date: 到海域之世 March, 1985

5. Total Direct Cost: US\$1700.00

6. Scientific Program Head:

This protocol has been approved by the 1)/seast / Causmission

Working Group.

Signature of Scientific Program Head:

Abstract Summary 7.

> Despite the plethora of data relating the protective effect of breastfeeding (BF) against infection, title is known about the role of BF in reducing the severity of infection, or about the effects of BF against diarrhoea due to specific pathogens. Using a case-control approach, with the cases defined as severely ill patients and the controls defined as non-severely ill patients, we will examine protection due to breast-feeding against rotavirus, Campylobacter, and ETEC in patients. 0-35 months of age who have been included in the hospital surveillance program of ICDDR, B between January 1, 1980, and January 1, 1983.

C;

(a)	Research Involving Human Subjects:	<u>;</u>
(b)	Research Review Committee:	<u></u>
(c)	Director:	

SECTION II - RESEARCH PLAN

INTRODUCTION:

Little is known about the role of breast-feeding in reducing the severity of diarrhoea. What little data that does exist suggests that diarrhoea hospitalization and mortality are reduced (1-6). However, these studies are, in large part antiquated (5 of 6 were conducted before 1940), they have not addressed protection against specific pathogens, and they have not examined protection beyond two years of age — although 20% or more of Bangladeshi women breast-feed to 35 months of age.

In this study, we plan to use the ICDDR,B hospital surveillance data to examine the possibility that breast-feeding does reduce the severity of diarrhoea due to specific pathogens. In one preliminary case-control analysis, we have found that in diarrhoea due to Shigella, breast-feeding does indeed reduce the severity of diarrhoea, and importantly this protection extends well beyond infancy and even to 35 months of age. We now propose to evaluate the effect of breast-feeding for the following additional pathogens which are common in young children: Campylobacter, rotavirus, and ETEC.

Methods:

a. General

The analyses will be conducted using the case-control technique. For each pathogen, cases will be severely ill patients with the pathogen, and controls will be non-severely patients with the pathogen.

Antecendent breast feeding histories in the two groups will be compared to assess protection.

b. Overall Eligibility

For each analysis, cases and controls will be selected from those patients in the Surveillance Program who were O-35 months of age at presentation between 1980-82 and in whom the pathogen of interest was the only pathogen isolated. Candidate "pathogens" for this purpose will include Shigella, Salmonella, ETEC, Campylobacter, V. cholerae, rotavirus, E. histolytica (trophozoites), and Giardia (trophozoites).

c. Cases

Cases will be defined as patients who were hospitalized, who died, or who had one or more of the following manifestations at the time of presentation: temperature 7102°F, severe neurologic manifestations (coma, seizuires), or severe dehydration.

d. Controls

Controls will be patients lacking any of the criteria for defining cases.

e. Breast-feeding Histories and Other Pertinent Data

This information is routinely acquired at the time of presentation in the Surveillance Program.

f. Analyses

For patients infected with each pathogen, the odds ratio relating breast-feeding to severity will be calculated. It can be shown

that this odds ratio reflects the reduction in severe disease, relative to the overall reduction of diarrhoea due to each pathogen. Thus, the odds ratio reflects the change in the spectrum of disease severity due to each pathogen. To rule out confounding bias, the odds ratios will be adjusted for age, gender, family size and income, nutritional status and other potential confounding variables. This adjustment will be performed using standard Mantel Haenzel technique for single confounders, and logistic regression to examine joint confounding by several variables. In addition, subgroup analyses will be performed to examine whether any factors modulate the degree of protection by breast-feeding; statistical distinctiveness of the subgroups will be evaluated using second order interaction terms in logistic models.

g. Significance

Reduction of disease severity by breast-feeding is an important yet little researched possibility. Our preliminary work suggests a prolonged beneficial effect in this regard against shigellosis. The present study will extend these observations to other common pathogens. The results will be of considerable importance to public health planners in comtemplating recommendations for breast-feeding in developing countries.

Abstract Summary

1. Study Population:

The ICDDR, B Surveillance population seen between 1980-82 will be used.

2. Risks

None

3. Not relevant

4. Confidentiality

Confidentiality is already preserved in the Surveillance Program, which has been approved by the ERC and RRC.

- 5. Not relevant
- 6. No interview will be involved.
- 7. Benefits include an improved understanding of the protection conferred by breast-feeding against specific diarrhoeal pathogens.
- 8. Surveillance records will be used. No other specimens will be used.

BUDGET

		Requirements	(Dollars)
1.	Personnel	0	
2.	Supplies		
	Office supplies and xeroxing	\$100	
3.	Equipment	0	
4 & 5,	Hospitalization, Outpatient Care	0	
6,	Transport - ICDDR,B	0	
7 & 8.	Transport of Things	0	
9.	Rent	О	
10.	Printing	Ο,	
11.	Other Contractual Time		>
	Programming	\$800	
	Computer time (100 hours)	\$800	

Total:

\$1700

Ē,